Logo

Immunocore Entered into an Agreement with Gadeta to Develop Gamma Delta TCR ImmTAC for Solid Tumors

Share this

Immunocore Entered into an Agreement with Gadeta to Develop Gamma Delta TCR ImmTAC for Solid Tumors

Shots:

  • Gadeta will receive an up front, near-term option fee & research milestones & is eligible to receive development & commercial milestones along with royalties if Immunocore exercises its option for an exclusive license
  • Under the research collaboration, Immunocore to get an option to develop ImmTAC therapies from ‘201 TCR & get an exclusive license option to research, develop & commercialize ImmTAC candidates
  • The agreement combines Gadeta’s gamma delta target & TCR identification expertise with Immunocore’s TCR bispecific engineering, development & commercialization capabilities to develop γδ-ImmTAC therapies. GDT201 showed promising results in the pre-clinical studies in colorectal cancer cell lines & the P-I trial is expected to initiate in H2’23 for solid tumor

Ref: Compass Therapeutics Image: Compass Therapeutics

Click here to­ read the full press release 

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions